Biolight Life Sciences Ltd. (BOLT) $BOLT
BioLight Reports Successful Feasibility Clinical Study Results for the Detection of Prostate Cancer with CellDetect® Non-Invasive Test
PR Newswire - Tue Jul 26, 6:00AM CDT
BioLight Life Sciences Ltd. (TASE: BOLT) ("BioLight" or the "Company"
, an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions and also in innovations in cancer diagnostics, announced promising results from a feasibility clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect® technology. The study successfully demonstrated the feasibility of detecting intact cells originating in the prostate from urine samples following prostate massage.
BOLT: ()
BioLight Expands Its Product Portfolio With Eye Drops for Dry Eye Syndrome
PR Newswire - Thu May 19, 7:59AM CDT
BioLight Life Sciences Ltd. (TASE: BOLT), ("BioLight" or the "Company", an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, announced today that it has obtained the worldwide rights (excluding Israel and Italy) for the manufacturing, distribution, marketing and sales of a groundbreaking new eye drop product for the treatment of dry eye syndrome (DES) and other ophthalmic indications. The product was in-licensed by BioLight from Fischer Pharmaceuticals Ltd. and RAMOT, the technology transfer arm of the Tel Aviv University. The product has CE Mark marketing approval in Europe, and BioLight is currently evaluating the clinical and regulatory efforts required to commercialize it in other territories around the world.
BOLT: ()
BioLight Announces First IOPtiMate(TM) System Sale in Hungary
PR Newswire - Mon Apr 13, 6:00AM CDT
BioLight Life Sciences Investments Ltd. (TASE: BOLT)(OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate(TM) system to a medical center located in Hungary.
BOLT: ()
Teledyne Completes Acquisition of Bolt Technology Corporation
BusinessWire - Tue Nov 18, 3:30PM CST
Teledyne Technologies Incorporated (NYSE:TDY) ("Teledyne" announced today the completion of the acquisition of Bolt Technology Corporation ("Bolt". At a special meeting of shareholders held November 17, 2014, Bolt shareholders voted to approve the adoption of the previously announced Agreement and Plan of Merger, dated September 3, 2014, by and among Teledyne, Lightning Merger Sub, Inc., a wholly-owned subsidiary of Teledyne, and Bolt.
TDY: 105.34 (+0.34), BOLT: ()
Bolt Technology Corporation Shareholders Approve Acquisition by Teledyne Technologies Incorporated
GlobeNewswire - Mon Nov 17, 10:45AM CST
Bolt Technology Corporation (Nasdaq:BOLT) ("Bolt" announced that at the special meeting of Bolt shareholders held today, Bolt's shareholders voted to approve the adoption of the previously announced Agreement and Plan of Merger, dated September 3, 2014, by and among Teledyne Technologies Incorporated ("Teledyne", Lightning Merger Sub, Inc., a wholly-owned subsidiary of Teledyne, and Bolt.
TDY: 105.34 (+0.34), BOLT: ()
Merriman Capital Initiates on BioLight Life Sciences Investments Ltd. with a Buy Rating
Thomson Reuters ONE - Thu Oct 30, 8:00AM CDT
SAN FRANCISCO - October 30, 2014 - Merriman Capital, Inc. ("Merriman", a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced that it has initiated equity research coverage of BioLight Life Sciences Investments Ltd. (OTCQX: BLGTY) with a Buy rating and a $12.00 price target.
BOLT: ()
Bolt Technology Corporation Announces Filing of Its Annual Report on Form 10-K and Amendment No. 1 to Its Annual Report on Form 10-K
GlobeNewswire - Tue Oct 28, 12:00PM CDT
Bolt Technology Corporation (Nasdaq:BOLT) filed its Annual Report on Form 10-K for the year ended June 30, 2014 (the "Annual Report on Form 10-K" with the Securities and Exchange Commission ("SEC" or the "Commission" on September 12, 2014, and filed Amendment No. 1 to its Annual Report on Form 10-K with the SEC on October 28, 2014.
BOLT: ()
BioLight to Present its IOPtiMate(TM) System at the Ophthalmology Innovation Summit @ the American Academy of Ophthalmology 2014
PR Newswire - Mon Oct 13, 8:00AM CDT
BioLight Life Sciences Investments Ltd.(TASE: BOLT)(OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that Ronen Castro, CEO of its subsidiary IOPtima Ltd., will present at the OIS@AAO (Ophthalmology Innovation Summit @ the American Academy of Ophthalmology) on Thursday, October 16, 2014, at 10:55 a.m. at the Palmer House Hilton in Chicago, IL.
BOLT: ()
BioLight Reports Successful Feasibility Clinical Study Results for the Detection of Prostate Cancer with CellDetect® Non-Invasive Test
PR Newswire - Tue Jul 26, 6:00AM CDT
BioLight Life Sciences Ltd. (TASE: BOLT) ("BioLight" or the "Company"
, an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions and also in innovations in cancer diagnostics, announced promising results from a feasibility clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect® technology. The study successfully demonstrated the feasibility of detecting intact cells originating in the prostate from urine samples following prostate massage. BOLT: ()
BioLight Expands Its Product Portfolio With Eye Drops for Dry Eye Syndrome
PR Newswire - Thu May 19, 7:59AM CDT
BioLight Life Sciences Ltd. (TASE: BOLT), ("BioLight" or the "Company"
, an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, announced today that it has obtained the worldwide rights (excluding Israel and Italy) for the manufacturing, distribution, marketing and sales of a groundbreaking new eye drop product for the treatment of dry eye syndrome (DES) and other ophthalmic indications. The product was in-licensed by BioLight from Fischer Pharmaceuticals Ltd. and RAMOT, the technology transfer arm of the Tel Aviv University. The product has CE Mark marketing approval in Europe, and BioLight is currently evaluating the clinical and regulatory efforts required to commercialize it in other territories around the world. BOLT: ()
BioLight Announces First IOPtiMate(TM) System Sale in Hungary
PR Newswire - Mon Apr 13, 6:00AM CDT
BioLight Life Sciences Investments Ltd. (TASE: BOLT)(OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate(TM) system to a medical center located in Hungary.
BOLT: ()
Teledyne Completes Acquisition of Bolt Technology Corporation
BusinessWire - Tue Nov 18, 3:30PM CST
Teledyne Technologies Incorporated (NYSE:TDY) ("Teledyne"
announced today the completion of the acquisition of Bolt Technology Corporation ("Bolt". At a special meeting of shareholders held November 17, 2014, Bolt shareholders voted to approve the adoption of the previously announced Agreement and Plan of Merger, dated September 3, 2014, by and among Teledyne, Lightning Merger Sub, Inc., a wholly-owned subsidiary of Teledyne, and Bolt. TDY: 105.34 (+0.34), BOLT: ()
Bolt Technology Corporation Shareholders Approve Acquisition by Teledyne Technologies Incorporated
GlobeNewswire - Mon Nov 17, 10:45AM CST
Bolt Technology Corporation (Nasdaq:BOLT) ("Bolt"
announced that at the special meeting of Bolt shareholders held today, Bolt's shareholders voted to approve the adoption of the previously announced Agreement and Plan of Merger, dated September 3, 2014, by and among Teledyne Technologies Incorporated ("Teledyne", Lightning Merger Sub, Inc., a wholly-owned subsidiary of Teledyne, and Bolt. TDY: 105.34 (+0.34), BOLT: ()
Merriman Capital Initiates on BioLight Life Sciences Investments Ltd. with a Buy Rating
Thomson Reuters ONE - Thu Oct 30, 8:00AM CDT
SAN FRANCISCO - October 30, 2014 - Merriman Capital, Inc. ("Merriman"
, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced that it has initiated equity research coverage of BioLight Life Sciences Investments Ltd. (OTCQX: BLGTY) with a Buy rating and a $12.00 price target. BOLT: ()
Bolt Technology Corporation Announces Filing of Its Annual Report on Form 10-K and Amendment No. 1 to Its Annual Report on Form 10-K
GlobeNewswire - Tue Oct 28, 12:00PM CDT
Bolt Technology Corporation (Nasdaq:BOLT) filed its Annual Report on Form 10-K for the year ended June 30, 2014 (the "Annual Report on Form 10-K"
with the Securities and Exchange Commission ("SEC" or the "Commission" on September 12, 2014, and filed Amendment No. 1 to its Annual Report on Form 10-K with the SEC on October 28, 2014. BOLT: ()
BioLight to Present its IOPtiMate(TM) System at the Ophthalmology Innovation Summit @ the American Academy of Ophthalmology 2014
PR Newswire - Mon Oct 13, 8:00AM CDT
BioLight Life Sciences Investments Ltd.(TASE: BOLT)(OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that Ronen Castro, CEO of its subsidiary IOPtima Ltd., will present at the OIS@AAO (Ophthalmology Innovation Summit @ the American Academy of Ophthalmology) on Thursday, October 16, 2014, at 10:55 a.m. at the Palmer House Hilton in Chicago, IL.
BOLT: ()
